Michael Linn
Impact in
- Pharmaceutical Science top 2%
- Drug Solubulity and Delivery Systems
- Advanced Drug Delivery Systems
- Oncology top 10%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
Papers in ⓘ
- Oncology 7
- HER2/EGFR in Cancer Research 3
- Cancer-related Molecular Pathways 2
-
- Angiogenesis and VEGF in Cancer 2
- Co-authors
- Karl Kolter (1 shared paper)Claus‐Michael Lehr (1 shared paper)Katja Hempel (1 shared paper)Dejan Djurić (1 shared paper)Eric Fabian (1 shared paper)Eva-Maria Collnot (1 shared paper)Kenneth Kolinsky (6 shared papers)Brian Higgins (5 shared papers)
- Journals
- Cancer Chemotherapy and Pharmacology (2 papers)Psychopharmacology (1 paper)Clinical Cancer Research (1 paper)Molecular Cancer Therapeutics (1 paper)Phytotherapy Research (1 paper)
- Partner nations
- United StatesSwitzerlandSerbia
In The Last Decade
Michael Linn
14 papers receiving 716 citations
Peers
Comparison fields: 5 of 97
- Pharmaceutical Science 159
- Oncology 247
- Molecular Biology 323
- Cellular and Molecular Neuroscience 67
- Cancer Research 55
Countries citing papers authored by Michael Linn
This map shows the geographic impact of Michael Linn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Linn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Linn more than expected).
Fields of papers citing papers by Michael Linn
This network shows the impact of papers produced by Michael Linn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Linn. The network helps show where Michael Linn may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Linn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 212 | |
| 2 | 2009 | 154 | |
| 3 | 2004 | 126 | |
| 4 | 2014 | 50 | |
| 5 | 2009 | 47 | |
| 6 | 2006 | 42 | |
| 7 | 2006 | 21 | |
| 8 | Antitumor activity of capecitabine and bevacizumab combination in a human estrogen receptor-negative breast adenocarcinoma xenograft model. | 2007 | 21 |
| 9 | 2010 | 14 | |
| 10 | 2013 | 11 | |
| 11 | 2011 | 10 | |
| 12 | 2013 | 10 | |
| 13 | 2006 | 8 | |
| 14 | 2013 | 3 |
About Michael Linn
Michael Linn is a scholar working on Oncology, Molecular Biology, Cellular and Molecular Neuroscience, Pulmonary and Respiratory Medicine and Cognitive Neuroscience, having authored 14 papers that have together received 729 indexed citations. Recurring topics across this work include Neurotransmitter Receptor Influence on Behavior (4 papers), Neuroscience and Neuropharmacology Research (4 papers), HER2/EGFR in Cancer Research (3 papers), Memory and Neural Mechanisms (2 papers), Cancer-related Molecular Pathways (2 papers), Angiogenesis and VEGF in Cancer (2 papers), Lung Cancer Treatments and Mutations (2 papers) and Drug Solubulity and Delivery Systems (1 paper). The work is most often cited by research in Pharmaceutical Science (159 citations), Oncology (247 citations), Molecular Biology (323 citations), Cellular and Molecular Neuroscience (67 citations) and Cancer Research (55 citations). Michael Linn has collaborated with scholars based in United States, Switzerland and Serbia. Frequent co-authors include Karl Kolter, Claus‐Michael Lehr, Katja Hempel, Dejan Djurić, Eric Fabian, Eva-Maria Collnot, Kenneth Kolinsky, Brian Higgins, Kathryn Packman and David Heimbrook. Their work appears in journals such as Cancer Chemotherapy and Pharmacology, Psychopharmacology, Clinical Cancer Research, Molecular Cancer Therapeutics and Phytotherapy Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.